Share
Cardiac-monitoring device maker Bardy Diagnostics has agreed to an acquisition by Hillrom, a medical technology provider specializing in smart hospital beds and other connected monitoring tools. The $375 million deal is expected to close during fiscal Q2 2021.
Bardy s flagship product is the Carnation Ambulatory Monitor, often referred to as the CAM patch. It s a P-wave signal-capturing wearable that is placed along the sternum, where it can remotely monitor patients’ cardiac activity or detect arrhythmia over a seven-day period. The patch s readings are uploaded to Bardy s companion patient management portal, which providers can use to access reports or receive monitoring alerts.
Health tech giant Hillrom to acquire Seattle startup Bardy Diagnostics for $375M
January 19, 2021 at 10:31 am
Dr. Gust Bardy, founder of Bardy Diagnostics. (Bardy Photo)
Hillrom, a publicly-traded medical device and digital health company based in Chicago, will pay $375 million to acquire Seattle startup Bardy Diagnostics.
Founded in 2013, Bardy set out to change the way medical professionals monitor heart conditions with a non-invasive cardiac monitor patch that helps detect arrhythmia. The Carnation Ambulatory Monitor, or CAM for short, is designed to be worn comfortably for approximately a week, with the goal of improving patient compliance. It uses a unique circuit design and algorithms to process P-wave recording. Bardy claims that its device captures clearer and more accurate heart rhythms than competing electrocardiography (ECG) monitors.
The projects’ intuitive interfaces and precision systems provide patients with proven respiratory therapies.
Global medical technology leader Hill-Rom Services Pte. Ltd. is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Its innovations help enable earlier diagnosis and treatment, optimise surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home.
Hillrom has recently launched two new respiratory therapy devices the Synclara™ Cough System and the Volara™ System, which provides hospital-grade oscillation and lung expansion (OLE) therapy.
OLE therapy has been proven to deliver clinical and economic outcomes in acute care settings. Recently published research in the Journal of American College of Surgeons showed that pulmonary treatment with OLE therapy, along with standard respiratory therapy,